US › Healthcare

Adial Pharmaceuticals Inc (ADIL)

US · Healthcare · Biotechnology

$3.80+4.40%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-2.0M
Profit YoY
+9.3%
EPS
$-1.48
EPS estimate
$-2.25

EPS came in at -1.48 against a street estimate of -2.25 — a beat of 34.2%.

Key statistics

Market cap
$7.3M
Forward P/E
0.0
P/B
1.98
Book value
$2.46
EPS (TTM)
$-4.93
52-week high
$11.47
52-week low
$1.31
50-day MA
$2.64
200-day MA
$4.15
Beta
1.43

Analyst view

Analysts rate Adial Pharmaceuticals Inc a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $7.00.

Shareholding

Insiders
4.32%
Institutions
28.20%

Largest institutional holders

FundStake
Geode Capital Management, LLC1.11%
China Universal Asset Mgmt Co.Ltd0.37%
Vanguard Fiduciary Trust Co0.27%
Manchester Capital Management LLC0.09%
Tower Research Capital LLC0.06%
BlackRock Inc0.05%
UBS Group AG0.02%
Vanguard Capital Management, LLC0.02%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Adial Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.